Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 3:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 189 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Paramyxoviridae Infections Clear all
Completed No phase listed Observational

Evaluation of Performance of the LumiraDx Influenza A/B + RSV Test at POC Testing Sites

NCT04288921
View directory record Official record
Conditions
Influenza, Human, Respiratory Syncytial Virus Infections
Interventions
Swab
Diagnostic Test
Lead sponsor
LumiraDx UK Limited
Industry
Eligibility
Not listed
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
20
States / cities
Birmingham, Alabama • Encinitas, California • Madera, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 5, 2026, 3:34 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control

NCT05705440
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 vaccine, Control
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
9 Years to 49 Years · Female only
Enrollment
3,855 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
27
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 5, 2026, 3:34 AM EDT
Completed No phase listed Observational

Idylla IFV-RSV Panel Clinical Testing

NCT02786381
View directory record Official record
Conditions
Respiratory Tract Infections, Influenza, Human, Respiratory Syncytial Virus Infections
Interventions
Not listed
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Industry
Eligibility
Not listed
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pensacola, Florida
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 5, 2026, 3:34 AM EDT
Recruiting Phase 3 Interventional

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

NCT03808922
View directory record Official record
Conditions
Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
Interventions
DAS181, Placebo, DAS181 COVID-19, DAS181 OL
Drug
Lead sponsor
Ansun Biopharma, Inc.
Industry
Eligibility
Not listed
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
23
States / cities
Duarte, California • Sacramento, California • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 5, 2026, 3:34 AM EDT
Terminated Phase 2 Interventional Results available

Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection

NCT06784973
View directory record Official record
Conditions
RSV Infection
Interventions
Obeldesivir, Obeldesivir Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
Up to 5 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
41
States / cities
Birmingham, Alabama • Oneonta, Alabama • Phoenix, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 5, 2026, 3:34 AM EDT
Completed Phase 2 Interventional Results available

Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children

NCT04484935
View directory record Official record
Conditions
RSV Infection
Interventions
Nirsevimab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
0 Years to 2 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Los Angeles, California • Tampa, Florida • Syracuse, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 5, 2026, 3:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to Recombinant Live-Attenuated Parainfluenza Type 1 Virus Vaccine

NCT00641017
View directory record Official record
Conditions
Parainfluenza, Virus Diseases
Interventions
rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 49 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 25, 2013 · Synced Oct 5, 2026, 3:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects

NCT04871724
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-938, Fluconazole
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 5, 2026, 3:34 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers

NCT04980391
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 49 Years · Female only
Enrollment
384 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 5, 2026, 3:34 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers

NCT04491877
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection
Interventions
RSV vaccine formulation 1, RSV vaccine formulation 2, Placebo
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 18 Months
Enrollment
259 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
25
States / cities
Gardena, California • La Mesa, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 5, 2026, 3:34 AM EDT
Completed No phase listed Observational

A Study to Investigate How Respiratory Syncytial Virus (RSV) Infection Develops and Changes Over Time in Pediatric Participants

NCT06746051
View directory record Official record
Conditions
RSV Infections
Interventions
Not listed
Lead sponsor
Shionogi
Industry
Eligibility
Up to 36 Months
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Syracuse, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 5, 2026, 3:34 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of BLB-201 RSV Vaccine in Infants and Children

NCT05655182
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
PIV5-vectored RSV Vaccine (BLB-201) Low Dose, PIV5-vectored RSV Vaccine (BLB-201) High Dose, Placebo
Biological · Drug
Lead sponsor
Blue Lake Biotechnology Inc.
Industry
Eligibility
6 Months to 5 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
18
States / cities
La Mesa, California • Modesto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 5, 2026, 3:34 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Predictors of Measles Vaccine Hesitancy in New York State

NCT07373093
View directory record Official record
Conditions
Measles Vaccination
Interventions
Survey
Other
Lead sponsor
Albany Medical College
Other
Eligibility
Not listed
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 5, 2026, 3:34 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above

NCT06389487
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
16
States / cities
Glendale, Arizona • Phoenix, Arizona • North Hollywood, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 5, 2026, 3:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children

NCT03596801
View directory record Official record
Conditions
RSV Infection
Interventions
RSV 6120/∆NS1, RSV 6120/F1/G2/∆NS1, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 59 Months
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 5, 2026, 3:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age

NCT02794870
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV LID ΔM2-2 1030s vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 24 Months
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
8
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 5, 2026, 3:34 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant

NCT04933968
View directory record Official record
Conditions
Respiratory Tract Viral Infections, Human Metapneumovirus (hMPV) Infection, Parainfluenza (PIV) Infection, Respiratory Syncytial Viral (RSV) Infection, Influenza Infection
Interventions
ALVR106, Placebo
Biological
Lead sponsor
AlloVir
Industry
Eligibility
17 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 5, 2026, 3:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants

NCT04126213
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT 60 µg, RSV MAT 120 µg, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
534 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
13
States / cities
Phoenix, Arizona • Huntington Park, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 5, 2026, 3:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women

NCT04138056
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 formulation 3, RSVPreF3 formulation 2, Boostrix-ex-US, Boostrix-US, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
509 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
4
States / cities
Miami, Florida • Lenexa, Kansas • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 5, 2026, 3:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults

NCT02873286
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
MVA-BN-RSV, Placebo
Biological · Other
Lead sponsor
Bavarian Nordic
Industry
Eligibility
55 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
12
States / cities
Redding, California • San Diego, California • The Villages, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 5, 2026, 3:34 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

300 Antibody Diagnostic Test Kit

NCT01646411
View directory record Official record
Conditions
Acute Bacterial Infections, Acute Viral Infections
Interventions
Not listed
Lead sponsor
The Plasma Source
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Southampton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2012 · Synced Oct 5, 2026, 3:34 AM EDT
Completed Phase 3 Interventional Results available

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

NCT00129766
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
motavizumab (MEDI-524), palivizumab
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
Up to 24 Months
Enrollment
6,635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
120
States / cities
Birmingham, Alabama • Pike Road, Alabama • Phoenix, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Oct 5, 2026, 3:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Safety and Pharmacokinetics Study of Single Ascending Doses of BTA-C585 in Healthy Volunteers

NCT02558413
View directory record Official record
Conditions
Pharmacokinetics, Healthy Volunteers
Interventions
BTA-C585 oral capsules, BTA-C585 matching placebo
Drug
Lead sponsor
Biota Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 5, 2026, 3:34 AM EDT
Completed Phase 2 Interventional Results available

Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract

NCT02254421
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection
Interventions
Presatovir, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
11
States / cities
Duarte, California • Chicago, Illinois • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Oct 5, 2026, 3:34 AM EDT